Abstract 286P
Background
Biomarker testing transforms NSCLC treatment, improving outcomes with targeted therapies.1–3 However, systematic barriers in EU limit patient access to comprehensive biomarker testing, negatively impacting care.4,5 To tackle these issues, Sanofi convened OncoCollective (OC), a multi-disciplinary stakeholder collaborative of global experts, to explore solutions.
Methods
The OC Precision Medicine Working Group developed an illustrative case study to map the patient journey in a specific EU country (Italy), facing biomarker testing barriers vs a patient journey with fewer barriers. The group reviewed existing outcomes data to estimate the potential impact on progression-free survival (PFS) between the two patient journeys.6,7
Results
The illustrative patient journey demonstrated that optimized biomarker-driven care with fewer barriers enabled more efficient personalized care and extended PFS across multiple lines of therapy in accordance with ESMO guidelines. In contrast, a journey fraught with barriers such as limited access, inadequate sampling, and delays in testing could result in suboptimal treatment sequencing and a vastly reduced PFS.
Conclusions
The findings highlight by overcoming biomarker testing barriers in NSCLC allowing guideline-indicated therapy may significantly improve patient outcomes. Proposed OC solutions to overcome barriers included a) providing educational programs, b) advocating for mandatory testing guidelines, c) appealing to payers and policymakers to invest in innovations, d) fostering partnerships to collect real-world evidence. Collaborative, multidisciplinary efforts across sectors are essential to translate scientific advances into meaningful improvements in outcomes for all NSCLC patients.
Legal entity responsible for the study
Sanofi.
Funding
Sanofi.
Disclosure
A. Bayle: Other, Personal, Principal Investigator, As a part of the Drug Development Department (DITEP) is a principal/sub-investigator of clinical trials: AbbVie, Adaptimmune, Adlai Nortye USA Inc, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Astex Pharmaceuticals, AstraZeneca Ab, Aveo, Basilea Pharmaceutica International Ltd, Bayer Healthcare Ag, Bbb Technologies Bv, BeiGene, BicycleTx Ltd, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co, Clovis Oncology, Cullinan-Apollo, Curevac, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Faron Pharmaceuticals Ltd, Forma Tharapeutics, Gamamabs, Genentech, GSK, H3 Biomedicine, Hoffmann La Roche Ag, Imcheck Therapeutics, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Iteos Belgium SA, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncopeptides, Orion Pharma, Ose Pharma, Pfizer, Pharma Mar, Pierre Fabre, Medicament, Roche, Sanofi Aventis, Seattle Genetics, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Turning Point Therapeutics, Xencor; Financial Interests, Personal, Research Grant: AstraZeneca, BMS, Boehringer Ingelheim, GSK, INCA, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; Non-Financial Interests, Personal, Other, Received non-financial support (drug supplied): AstraZeneca, Bayer, BMS, Boehringer Ingelheim, GSK, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche; Financial Interests, Personal, Other, Reports consulting fees for advisory board: Sanofi, Roche; Financial Interests, Personal, Other, Travel: Pfizer, Bayer. M.S. Aapro: Financial Interests, Personal, Invited Speaker: Sanofi, Amgen; Financial Interests, Personal, Advisory Board, Advisory board member: Astellas; Financial Interests, Personal, Invited Speaker, Receiving grants and other funding: AstraZeneca, BMS, Daiichi Sankyo, ExactSciences, Fresenius Kabi, Helsinn, Mundipharma, Novartis, Pfizer, Roche, ViforPharma; Financial Interests, Personal, Member of Board of Directors, Receiving grants and other funding: ALL CAN, SIOG, SPCC, UICC; Non-Financial Interests, Personal, Advisory Role, Advisory role and Membership: ASCO, MASCC, SBOC; Financial Interests, Personal, Leadership Role: European Cancer Organisation, SIOG, SPCC; Financial Interests, Personal, Member, Serves as a SAB member of the European School of Oncology: European School of Oncology. P.J. Lamy: Financial Interests, Personal, Other, Received travel expenses: Roche; Other, Personal, Other, Board Member: AstraZeneca. M. Maio: Financial Interests, Personal, Other, Received consulting fees: GSK, Bristol Myers Squibb, AstraZeneca, Roche, MSD, Merck, Pierre Fabre, Alfasigma, Eli Lilly, Sanofi, Amgen, Sciclone, Incyte; Financial Interests, Personal, Speaker’s Bureau, Received payment or honoraria for lectures, presentations, speaker bureaus: GSK, Bristol Myers Squibb, AstraZeneca, Roche, MSD, Merck, Pierre Fabre, Alfasigma, Eli Lilly, Sanofi, Amgen, Sciclone, Incyte; Other, Personal, Advisory Board, Participated on data safety monitoring boards or advisory boards: Sanofi, Alfasigma, Amgen, Sciclone, Incyte, Pierre Fabre, Eli Lilly, GSK, Bristol Myers Squibb, AstraZeneca, Roche, Merck; Financial Interests, Personal, Stocks/Shares: Epigen Therapeutics, Theravance. A. Palmer: Financial Interests, Personal, Other, Received consulting fees: AstraZeneca, Kymera, Merck, Novartis, Sanofi; Financial Interests, Personal, Funding, Research funding: Prelude Therapeutics. E. Szmytke: Financial Interests, Personal, Invited Speaker: LuCE; Financial Interests, Institutional, Funding, Develops multi-sponsored projects: Amgen, AstraZeneca, Bayer, Blueprint, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Gilead, Janssen, Lilly, Merck, MSD, Novartis, Novocure, Pfizer, Regeneron, Roche, Sanofi, Takeda, ThermoFisher; Other, Personal and Institutional, Advisory Board, Take part in Patient Advisory Boards and other patient advocacy related consultation: Amgen, AstraZeneca, Bayer, Blueprint, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Janssen, Lilly, Merck, MSD, Novartis, Novocure, Pfizer, Regeneron, Roche, Sanofi, Takeda; Other, Institutional, Advisory Board, Take part in Patient Advisory Boards and other patient advocacy related consultation: ThermoFisher. K. Paranjpe, C. Fernandez: Financial Interests, Personal, Full or part-time Employment, Employees of Sanofi and may hold shares and/or stock options in the company: Sanofi.: H. Hansen: Financial Interests, Personal, Full or part-time Employment: Sanofi. A. Lopez Galnares: Financial Interests, Personal, Invited Speaker, Employees of Sanofi and may hold shares and/or stock options in the company: Sanofi. M. Caschetta, R. Goeckeler, E. Lee: Financial Interests, Personal, Full or part-time Employment, Employees of the agency hired by Sanofi to work on OncoCollective: Sanofi. All other authors have declared no conflicts of interest.